Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and onco-dermatology. Founded and incorporated on June 28, 2021, the company is headquartered in London, United Kingdom. Vidac Pharma specializes in the discovery and development of treatments that aim to target the tumor microenvironment by reprogramming cancer cell metabolism to hinder tumor progression. The company's lead compound, VDA-1102, is an anti-neoplastic agent currently undergoing Phase 2B clinical trials for the treatment of actinic keratosis and cutaneous T-cell lymphoma. Additionally, Vidac Pharma is developing VDA-1102 IV and VDA-1275, a small molecule treatment currently in preclinical development for solid tumors. Vidac Pharma's shares are listed on the Düsseldorf Stock Exchange's Open Market, XETRA, and Tradegate under the ticker symbol T9G, with an ISIN of GB00BM9XQ619. As of July 9, 2026, the stock was priced at €0.4750, with a market capitalization of approximately €24.47 million. The company maintains a robust intellectual property portfolio that includes seven global patent families for its cancer therapeutics. Leadership is provided by Prof. Max Herzberg, who serves as CEO. Notably, in December 2025, Vidac Pharma's shares were successfully listed on the Düsseldorf Stock Exchange's Open Market, representing a key milestone in its growth strategy. In July 2026, Eutopos Pharma, its French affiliate, was selected to join Quest for Health, indicating an expansion within Europe's biotech sector.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
VIDAC PHARMA HOLDING PLC's offering is currently approved on OTHER. VIDAC PHARMA HOLDING PLC is headquartered in Germany. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with VIDAC PHARMA HOLDING PLC.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/vidac-pharma" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="VIDAC PHARMA HOLDING PLC — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/vidac-pharma?theme=light as the src instead.
https://www.discoveripo.com/ipo/vidac-pharma/opengraph-image
VIDAC PHARMA HOLDING PLC IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/vidac-pharma?utm_source=embed&utm_medium=text&utm_campaign=vidac-pharma
Get emailed when VIDAC PHARMA HOLDING PLC's terms, price, or expected date change — no weekly noise, just this company.
VIDAC PHARMA HOLDING PLC is listing on OTHER.
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and onco-dermatology. Founded and incorporated on June 28, 2021, the company is headquartered in London, United Kingdom. Vidac Pharma specializes in the discovery and development of treatments that aim to target the tumor microenvironment by reprogramming cancer cell metabolism to hinder tumor progression. The company's lead compound, VDA-1102, is an anti-neoplastic agent currently undergoing Phase 2B clinical trials for the treatment of actinic keratosis and cutaneous T-cell lymphoma. Additionally, Vidac Pharma is developing VDA-1102 IV and VDA-1275, a small molecule treatment currently in preclinical development for solid tumors. Vidac Pharma's shares are listed on the Düsseldorf Stock Exchange's Open Market, XETRA, and Tradegate under the ticker symbol T9G, with an ISIN of GB00BM9XQ619. As of July 9, 2026, the stock was priced at €0.4750, with a market capitalization of approximately €24.47 million. The company maintains a robust intellectual property portfolio that includes seven global patent families for its cancer therapeutics. Leadership is provided by Prof. Max Herzberg, who serves as CEO. Notably, in December 2025, Vidac Pharma's shares were successfully listed on the Düsseldorf Stock Exchange's Open Market, representing a key milestone in its growth strategy. In July 2026, Eutopos Pharma, its French affiliate, was selected to join Quest for Health, indicating an expansion within Europe's biotech sector.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy